At Snowfish, our cross-functional team of industry professionals provides thought leadership on topics of importance to pharmaceutical, medical device, and biotechnology companies through articles, white papers and proprietary study reports. We offer solutions as a result of our insights.
We invite you to take advantage of these life science insights through the vehicles provided.
KOL Identification and Profiling
- Investigators of clinical trials
- Authors of journal articles
- Editorial board members of journals
- Association officers
- Administrative positions at hospitals and universities
- Guideline authors
- Speakers at conventions and symposia
- Program planners
- Physicians at top-rated hospitals
- Hospitals conducting high numbers of related procedures
- National speakers
- Regional speakers
- Advisory board members
Strategic Product Development
- Physician interviews
- Procedure and diagnostic data
- Stock analyst reports
- Clinical trial results
- Association data
- Corporate websites
- Press releases
- NIH data
- Annual reports
- SEC filings
- AMA data
- Physician interest
- Product differentiation
- Patient interest
- Product revenue
- Market profitability
- Entry barriers
- Market growth
- Distribution/physician population
- Competitive intensity
- Rate of adoption
- Untreated patient population
|External Factor||Product A||Product B||Product C||Product D||Product E|
|Rate of Adoption||9||7||2||1||3|
Product Development Research
|Total Interventional Cardiologists||16||5||7||16||13|
|Interventional Cardiologist Trained on Procedure||1||1||2||4||2|
|Product A||Study A initiates||Data from Study B presented at Association meeting||Study C to release interim results|
|Product B||New indication approval||Study R expected completed|
|Product C||Results from Study S||Study Y should be completed||Interim results of Study J|
|Product D||Study Z results to be presented at Association meeting||Results from Study F||Interim results of Study P||Study O initiates|
|Product E||Study V initiates||Data from Study N presented at Association meeting||Interim results of Study L||Study M expected completed|
|Product A||New indication for PCI (end of XXX?). Promote efficacy of XXX regimen in both UA/NSTEMI and STEMI patients undergoing PCI. Leverage data from XXX along with other data in STEMI including XXX and studies by XXX et al.|
|Product B||May be pushing to continue to capture patients eligible for early administration of eptifibatide. May position as optimal GP IIb/IIIa inhibitor to be used with early invasive strategy.|
|Product C||Continue efforts to expand use upstream in AMI patients planned for angioplasty.|
|Product D||Depending upon what XXX shows, focus may be on either replacing heparin or GP IIb/IIIa inhibitors in upstream management of UA/NSTEMI patients. Focus of strategy and indication will depend upon the results.|
|Product E||May leverage XXX to support role of high-dose clopidogrel in a new standard of care, however may still promote benefit of the high-dose without the need for the addition of a GP IIb/IIIa inhibitor.|
Strategic Partnering Case Study
- Articles published by investigators at organization
- Guidelines published by investigators at organization
- Clinical trials conducted at the organization (and how many were sponsors vs. locations)
- NIH grants awarded to organization
- If the organization had relevant fellowship program
- Current relationships between the company and investigators within the organization
- Community involvement
- Various measures of alignment
SHOWCASE FEATURE: Medical Affairs: Beyond the Science (quoted). PharmaVOICE, Hammond, Melissa, April 2013.
Genomic Innovation (quoted). PharmaVOICE, Fishman, David, March 2013.
The C-Suite: Corporate Strategies (quoted). PharmaVOICE, Hammond, Melissa, Nov/Dec 2012.
Sales: New Strategies (quoted). PharmaVOICE, Fishman, David, Nov/Dec 2012.
Crystal Ball: What’s Ahead (quoted). PharmaVOICE, Hammond, Melissa, Nov/Dec 2012.
Competitive Intelligence and Strategy in Today’s Environment (quoted). PharmaVOICE, Hammond, Melissa, April 2012.
Payers Play Larger Role In PostLaunch Strategies (quoted). PharmaVOICE, Hammond, Melissa, March 2012.
Molecule to Market – Along the Continuum (quoted). PharmaVOICE, Fishman, David, March 2012.
Market Capitalization (quoted). PharmaVOICE, Hammond, Melissa, March 2012.
The C-Suite: Corporate Strategies (quoted). PharmaVOICE, Fishman, David. Nov/Dec 2011.
Building a Culture of Innovation: Fostering Innovation (quoted). PharmaVOICE, Fishman, David. Nov/Dec 2011.
A Changing Rhythm (quoted). PharmaVOICE, Fishman, David. June 2011.
Clinical Data Gap Analysis: Uncovering Hidden Opportunities. PharmaVOICE, Fishman, David. June 2011.
KOL Mapping: The GPS of Thought Leader Identification (quoted). PharmaVOICE, Fishman, David. April 2011.
R&D Innovation: The Key to Long-Term Success (quoted). PharmaVOICE, Fishman, David. March 2011.
Healthcare Reform and Comparative Effectiveness (quoted). PharmaVOICE, Fishman, David. Nov/Dec 2010.
What Was Old is New Again (3 trends). PharmaVOICE, Fishman, David. Nov/Dec 2010.
Buzzword for Tomorrow’s Sales Reps: Consultancy (quoted). PharmaVOICE, Hammond, Melissa. Nov/Dec 2010.
Nurse Practitioners and Physician Assistants: Taking a Closer Look (quoted). HBA Advantage, Hammond, Melissa. Fall 2010.
Tomorrow’s MSL: Specialist or Generalist (quoted). PharmaVOICE, Fishman, David. October 2010.
Midlevel Healthcare Providers: An Untapped Prescribing Force (quoted). PharmaVOICE, Hammond, Melissa. September 2010.
Adaptive by Design (quoted). PharmaVOICE, Hammond, Melissa. June 2010.
Safety evaluation of tirofiban. Expert Opin Drug Saf. Valgimigli M, Tebaldi M. 2010;9(5):801-19.
Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban. Drugs. van’t Hof AW, Valgimigli M. 2009; 69(1): 85-100.
Low-molecular-weight heparins in acute myocardial infarction: rationale and results of a pilot study. Clin Cardiol. Ross AM, Coyne K, Hammond M, Lundergan CF. July 2000; 23(7): 483-5.
Changes in bedrail prevalence during a bedrails-reduction initiative. Journal of the American Medical Directors Association. Levine JM, Hammond M, Breuer B. 2000; 1:34-36.
Bedrails: choosing the best alternative. Geriatric Nursing. Review.1 Hammond M, Levine JM. Nov-Dec 1999; 20. (6): 297-300; quiz 300-1. Review.1
Falls and related injuries in the nursing home: the importance of time and place. (Abstract presented at Alzheimer’s Association Annual Meeting, Chicago IL). Levine JM, Hammond M, Breuer B. July 1997.
Bedrail use. (Letter to the editor). Journal of the American Geriatric Society. 45(6): 780-1 Levine JM, Hammond MH. June 1997.
Epidemiology of falls and related injuries in a large nursing facility. (Abstract presented at American Geriatrics Society Annual Meeting, Los Angeles CA). Levine JM, Hammond M, Pruchnicki A, Shelky M, Totolos E, Breuer B. May 1997.
Characteristics of residents with bedrails in a large academic nursing facility. Journal of the American Geriatrics Society. Levine JM, Hammond M, Marchello V, Breuer B. 1996; 44: S72 (abstract).
Epidemiology of bedrails in a large long-term care facility. The Gerontologist. Hammond MH, Levine JM, Marchello V, Breuer B. 1995; 35: SI369 (abstract).
Bedrails: Under-represented in the medical literature. The Gerontologist. Marchello V, Levine JM, Hammond M, Breuer B. 1995; 35: SI211 (abstract).
Bedrails: Physical restraint or enabler? The Gerontologist. Levine JM, Hammond M, Marchello V, Breuer B. 1995; 35: SI136 (abstract).
1Currently used as a reference in FDA materials on bed safety.
What do Mick Jagger, Diabetes, Heart Disease, and Cancer Have in Common?
Thought Leader: Melissa Hammond MSN, GNP, Managing Director, Snowfish LLC
In this episode: In this episode Melissa Hammond MSN, GNP, Managing Director at Snowfish speaks with Dan Limbach, Manager, Webcast Network at PharmaVOICE. They talk about our aging society and how the industry needs to address its therapies to reflect the differences in age groups, including the old and the very old. Download Podcast as Transcript